stockrow
Friday 6 November 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
15.78
1.59
+11.21%
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) EBITDA
Summit Therapeutics PLC's EBITDA for fiscal 2025 was −$1.1B, compared with −$225.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$872.8M. Over the past ten years it has ranged from −$1.1B (fiscal 2025) to $10.3M (fiscal 2019) — the current reading is the lowest in ten years. Summit Therapeutics PLC ranks 590th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$1.1B | — |
| FY2024 | −$225.9M | — |
| FY2023 | −$609.5M | — |
| FY2022 | −$69.6M | — |
| FY2021 | −$83.7M | — |
| FY2020 | −$51.2M | — |
| FY2019 | −$25.8M | — |
| FY2019 | $10.3M | — |
| FY2018 | −$34.2M | — |
| FY2018 | −$16.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$220.5M | — |
| Mar 2026 | −$189.4M | — |
| Dec 2025 | −$228.8M | — |
| Sep 2025 | −$234.2M | — |
| 45 more quarters | Free account |
Against its own ten years
Low −$1.1B
High $10.3M
Ten-year median
−$33.5M
Current reading's percentile
7
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| HALO Halozyme Therapeutics, Inc. compare | $719.2M |
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| KYMR Kymera Therapeutics, Inc. compare | −$405.5M |
| SMMT Summit Therapeutics PLC | −$872.8M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement